On
Compared with the previous influenza season (2023-2024 influenza season), the A(H3N2) virus in the recommended influenza vaccine strains for 2024-2025 has changed. )-like virus' was changed to 'A/
Quadrivalent influenza vaccine
A/ H1N1: A/Victoria/4897/2022 (H1N1)pdm09-like virus
A/ H3N2: A/
B Victoria lineage: B/
B/
Trivalent influenza vaccine
A/ H1N1: A/Victoria/4897/2022 (H1N1) pdm09-like virus
A/ H3N2: A/
B Victoria lineage: B/
The influenza vaccine antigens approved in my country are all based on chicken embryo cell culture
The above recommendations provide important guidance and reference for health departments and vaccine manufacturers in various countries to timely adjust and produce vaccines that adapt to the prevailing virus strains that year, so as to better respond to the arrival of the influenza season.
Influenza Vaccine and Influenza Epidemic Prevention and Control
Influenza (referred to as 'influenza') is an acute respiratory infectious disease caused by influenza viruses that seriously harms human health. Influenza viruses are antigenically variable and spread rapidly, causing seasonal epidemics every year. Outbreaks are prone to occur in places where people gather, such as schools, daycare institutions, and nursing homes.
According to
Since influenza viruses are prone to mutation, influenza strains may change every year, making it difficult for antibodies previously formed through natural infection or immunization to neutralize effectively, making the population generally susceptible.
Professional organizations, including the
As influenza viruses mutate, updating influenza vaccines is crucial to strengthening influenza prevention and control. By ensuring that influenza vaccines match current circulating virus strains, infection rates can be effectively reduced, the burden on the medical system can be reduced, and the adverse social and economic impacts of an influenza pandemic can be avoided.
Spring flu epidemic cannot be ignored
Influenza appears as a seasonal epidemic and high incidence in temperate regions every winter and spring.
Beginning in
About SINOVAC
The vaccines developed by SINOVAC mainly include vaccines against viral hepatitis, influenza, pneumonia, polio, chickenpox, mumps and other common infectious diseases, as well as vaccines against SARS, H5N1 avian influenza, H1N1 pandemic influenza, EV71 hand, foot and mouth disease, novel Vaccines for emerging and emerging infectious diseases such as coronavirus infections.
The company's current 4 vaccines have passed
SINOVAC is constantly exploring opportunities in the international market and has exported vaccines to dozens of countries and international organizations.
Contact:
Tel: +86-10-8289-0088
Fax: +86-10-6296-6910
Email: sinovac@sinovac.com
(C) 2024 Electronic News Publishing, source